HealthBiome Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HealthBiome Inc. - overview
Established
2017
Location
Daejeon-City, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2017 and based in Daejeon-City, South Korea, HealthBiome Inc. operates as a bio-venture company with its own effective strains for treating diseases. The company has carried out R&D in microbiome-based drug discovery using strict anaerobic gut microbiota identification and production technology. In December 2020, the company raised an undisclosed amount in series A funding.
The company has obtained 3 patents registration of the microbiome-based treatment for Alzheimer’s disease and 2 PCT applications. In September 2019, the company obtained a patent application for the microbiome-based treatment for cancer. HealthBiome’s research lab is studying the separation of human gut strict anaerobic microbial strains with excellent efficacy in treating cancer, brain nervous, aging diseases, and is also developing microbiome-based disease treatment substances. The company based on the separation technology of unculturable strict anaerobic gut microbiota has identified candidate strains with great efficacy of treating incurable diseases, and has secured its own microbes effective in improving immuno-oncology therapies, CNS disorders as well as metabolic syndromes.
The products of the company can be used in disease treatment, preventive functional foods, medical foods, cosmetics, animal medicines and health functional feed.
Current Investors
KDB Capital, Solidus Investment, L&S Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.healthbiome.co.kr
Company Stage
Series B
Total Amount Raised
Subscriber access only
HealthBiome Inc. - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | (299,460,000) | (404,731,000) | - | - | - |
| Operating Margin | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (185,849,000) | (443,788,000) | - | - | - |
| % Net Margin | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.